OCRA News
OCRA Now Accepting Applications for 2021 Research Grants
(June 11, 2020) Letters of Intent (LOIs) for Ovarian Cancer Research Alliance’s 2021 scientific grant awards are now open for submission. LOIs are due by July 10, 2020. Accepting LOIs is step one of OCRA’s highly competitive grant process…
Connecting Survivors to the Science | Meet a Research Advocate
To speak with Kimberly Richardson is to feel an instant camaraderie with someone who exhibits both calm and conviction, thoughtfulness and frank talk…
Convenient Spit Test Helps Women Assess Cancer Risk From the Comfort of Their Own Home
First-of-its-kind clinical trial validates remote genetic counseling (New York) June 01, 2020 – Genetic testing for cancer risk can significantly improve the prevention or treatment of hereditary cancers, but studies have shown that people who…
A Statement from OCRA
If there’s one thing that working toward an end to ovarian cancer has taught us, it’s that life is precious. We value the life of every person in our ovarian cancer community, and celebrate its diversity and strength…
Inspired Advice: What Do You Need Most from a Life Partner?
Those who have faced an ovarian or gynecologic cancer diagnosis have so much to offer to others going through a similar experience – be it support, tips or friendship…
Speaking Out for Those Who Can’t | OCRA Advocate Leader
In 2005, Denise Lobodinski’s sister Renee was diagnosed with ovarian cancer at the age of 47. That same year, their father was diagnosed with prostate cancer. But her father’s doctor told Denise’s mother, “Don’t worry about your husband…
Survey: Navigating Treatment in the Time of Covid-19
Covid-19 has disrupted nearly every aspect of life as we know it, and navigating a diagnosis and treatment for ovarian cancer – already a game changer – has been impacted as well…
Science Made Simple: Ovarian Cysts and Ovarian Cancer
Ovarian cysts are fairly common, but that doesn’t make having them any less nerve-wracking. If you’ve been diagnosed with an ovarian cyst, it’s natural to wonder if that means you have, or are at risk of developing, ovarian cancer…
When a Virus is a Good Thing | Meet a Scientist
Scared. Overwhelmed. Exhausted. Befuddled. These are common words one might use to describe how we feel during this unprecedented time in history…
Reflections from the Frontline | OCRA Scientists on Covid-19
We reached out to our grantees and Scientific Advisory Committee, many of whom are on the frontlines – working in hospitals, meeting with patients, seeing firsthand the impact of Covid-19. We wanted to hear their words and reflections…
Raising Awareness of the Unseen, Giving Voice to the Unheard | Survivor Stories
The world works in ironic and sometimes painful ways Yvette Jives, a nurse and social worker in North Carolina, has spent a lifetime helping others…
Niraparib Receives FDA Approval as First-Line Maintenance Therapy for Advanced Ovarian Cancer
(May 4, 2020) On April 29th, the Food and Drug Administration approved niraparib (Zejula, GlaxoSmithKline) as a first-line maintenance treatment for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer, regardless of BRCA…